Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314353 · ClinicalTrials.gov registry record · Phase 2
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
A Phase 2 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00314353: Clinical Trial Phase 2 study, sponsored by NSABP Foundation.
NCT00314353 is a Phase 2 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314353, a Phase 2 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.
Primary Outcome
Outcome measure was not assessed due to early study closure. The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Why NCT00314353 stopped before completion
NCT00314353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00314353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00314353 about?
NCT00314353 is a clinical study titled "Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon". Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the c...
What is the current status of trial NCT00314353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2006-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00314353?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00314353?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00314353's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia